| Cluster 1 | Cluster 2 | Cluster 3 | P-value |
---|---|---|---|---|
 | (N = 1,237) | (N = 662) | (N = 294) |  |
Male gender | 799 (64.6%) | 443 (66.9%) | 207 (70.4%) | 0.143 |
Age class (years at index date) | ||||
 18 - 29 | 632 (51.1%) | 351 (53.0%) | 221 (75.2%) | < 0.001 |
 30 - 40 | 605 (48.9%) | 311 (47.0%) | 73 (24.8%) |  |
Number of co-treatments: | ||||
 0 | 866 (70.0%) | 407 (61.5%) | 173 (58.8%) | <0.001 |
 1-2 | 351 (28.4%) | 247 (37.3%) | 121 (41.2%) |  |
     \(\ge 3\) | 20 (1.6%) | 8 (1.2%) | 0 (0.0%) |  |
Clinical statusa | ||||
 Good | 636 (51.4%) | 324 (48.9%) | 105 (35.7%) | <0.001 |
 Intermediate | 121 (9.8%) | 57 (8.6%) | 14 (4.8%) |  |
 Poor | 480 (38.8%) | 281 (42.5%) | 175 (59.5%) |  |
Weekly variety of treatments b: mean (SD) | ||||
 No treatments | 39.6 (12.2) | 5.0 (5.9) | 1.9 (3.0) | <0.001 |
 Low | 9.0 (9.6) | 23.0 (13.7) | 7.5 (6.5) |  |
 Medium | 2.9 (5.0) | 22.8 (13.9) | 17.9 (8.8) |  |
 High | 0.5 (2.2) | 1.2 (2.9) | 24.7 (12.2) |  |